<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0007131" disease_type="Neoplastic Process" abbrv="NSCLC">Non-small cell lung cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NSCLC</z:e>) is the most deadly type of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> worldwide </plain></SENT>
<SENT sid="1" pm="."><plain>Although a number of therapies are used in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NSCLC</z:e> treatment, their therapeutic efficacy remains low </plain></SENT>
<SENT sid="2" pm="."><plain>Lenalidomide was originally approved for use in patients with <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo>, which are associated with 5q deletions, and <z:hpo ids='HP_0006775'>multiple myeloma</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>Recently, lenalidomide was investigated as a new <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NSCLC</z:e> treatment, and it exerted anticancer effects </plain></SENT>
<SENT sid="4" pm="."><plain>However, the primary cellular mechanism of its effects in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NSCLC</z:e> is largely unknown </plain></SENT>
<SENT sid="5" pm="."><plain>Therefore, we attempted to elucidate a molecular portrait of lenalidomide-mediated cellular events in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NSCLC</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>Lenalidomide reduced the viability of several <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NSCLC</z:e> cell lines in a concentration-dependent manner </plain></SENT>
<SENT sid="7" pm="."><plain>In addition, array-based gene expression analysis revealed that lenalidomide regulated the expression of several genes associated with cell survival, <z:mpath ids='MPATH_3'>apoptosis</z:mpath> and development, including <z:chebi fb="0" ids="30153">BH3</z:chebi>-interacting domain <z:hpo ids='HP_0011420'>death</z:hpo> <z:chebi fb="4" ids="48705">agonist</z:chebi> (BID), v-fos FBJ murine <z:hpo ids='HP_0002669'>osteosarcoma</z:hpo> <z:mp ids='MP_0001799'>viral</z:mp> oncogene homolog (FOS) and NK2 homeobox1 (NKX2-1) </plain></SENT>
<SENT sid="8" pm="."><plain>BID and FOS, which are known <z:mpath ids='MPATH_3'>apoptosis</z:mpath> activators, were upregulated by lenalidomide treatment, whereas NKX2-1, which is used as an immunohistochemistry marker for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NSCLC</z:e>, was downregulated </plain></SENT>
<SENT sid="9" pm="."><plain>These results provide evidence that lenalidomide directly induces antiproliferative effects by altering the expression of genes associated with cell proliferation and <z:mpath ids='MPATH_3'>apoptosis</z:mpath> </plain></SENT>
</text></document>